Carcinoembryonic Antigen Market (2024 - 2030) Size, Share & Trends Analysis Report By Type (Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer), By Gender, By Product, By Test, By End Use, By Region, And Segment Forecasts

Carcinoembryonic Antigen Market Summary

There has been a significant surge in the annual number of cancers diagnoses worldwide over the last ten years. Increasing life expectancy is further leading to many people being diagnosed during their lifetime and therefore driving market growth. Technological advancements in proteomics, including protein bioinformatics, mass spectroscopy, protein labelling, imaging, and array-based methods, are leading to market expansion. The market growth is expected to be fueled by the emergence of new biomarkers and immunological techniques such as radioimmunoassay that can complement carcinoembryonic antigen (CEA) in detecting different cancer types. 

Type Insights & Trends

Breast cancer accounted for a share of 16.1% in 2023. Breast cancer is experiencing significant growth owing to the factors such as rising female population above 50 years, advancements in biomarkers and increase in number of patients undertaking hormone replacement therapy (HRT), breast augmentation & reconstruction surgery. Increasing government initiative coupled with rising consumer awareness for different treatment procedures is also driving the market growth. Moreover, other breast related diseases such as infections, lesions, and fibrocysts are also expected to contribute to the increase in early diagnosis.

Colorectal cancer is projected to witness a CAGR of 5.9% over the forecast period. Rising incidence of colorectal cancer and increase sensitivity to detect the antigen are the factors driving the growth of this segment. Furthermore, increased consumption of alcohol, less physical activity, unhealthy diet, and rapidly changing lifestyle also contribute in the growth of colorectal cancer.

Gender Insights & Trends

The female segment dominated the market with 63.3% of revenue share in 2023. This is owing to the increasing rate of breast cancer, which is the most widespread cancer that impacts women globally. According to National Cancer Institute of America, there are estimated 2,001,140 new cases of cancer in U.S. in 2024 and three most common types of cancers are colorectal, breast, and lung and these are expected to be 51% of new cancer diagnosis in women this year.

The male segment is anticipated to witness the fastest CAGR of 5.7% over the forecast period. Males are more prone to developing different cancers, possibly due to risk factors such as smoking and alcohol consumption. According to National Cancer Institute of America, the new cancer cases rate is 440.5 per 100,000 men & women every year. Prostate, colorectal, lung cancers are most common types of cancer occurring in male and these account for an estimated 48% of all cancers diagnosed in men in 2024. This data shows number of cancer cases in male are rising which is a significant growth factor of CEA market.

Product Insights & Trends

The CD66d segment accounted for the largest revenue share of 26.7% in 2023. CD66d is a type of carbohydrate antigen that can be found on the surface of specific cells in the human digestive system and certain cancer cells. CD66d serves as a tumor marker in different cancer types, especially in colorectal, pancreatic, and gastric cancers. Utilizing CD66d as a tumor marker enables the early identification and tracking of these cancers, resulting in potential enhancement of patient outcomes.

The CD66b segment is anticipated to grow at a CAGR of 9.2% over the forecast period. CD66b, a part of the GMA family, is found on myeloid lineage cells such as neutrophils and eosinophils. This molecule is highly expressed in various cancers including colorectal carcinoma, breast cancer, gastric carcinoma, ovarian carcinoma, and non-small cell lung carcinoma.

Test Insights &Trends

Molecular tests accounted for 59.4% market share in 2023. There is a growing popularity of molecular tests in cancer diagnostics owing to its high sensitivity and specificity. The purpose of these tests is to identify genetic mutations or alterations in DNA or RNA sequences linked to cancer. During CEA testing, molecular tests are utilized to pinpoint particular mutations that could result in higher CEA levels.

Serology tests are expected to grow at a CAGR of 5.1% during the forecast period. The concentration of CEA proteins in the blood is measured with immunochemical methods as ELISAs in these serology tests. Increased levels of CEA may suggest the presence of cancer or the progression of a tumor, making these tests important for screening, diagnosing, and monitoring cancer.

End Use Insights & Trends

Hospitals dominated the market with a share of 47.4% in 2023. Hospitals play a crucial role in offering extensive cancer care services, leading to a major portion of the CEA market being attributed to them. Hospitals play a vital role in connecting with patients at different points of cancer treatment. Their services include various diagnostic options, such as CEA testing, which assists in identifying cancer presence or recurrence. Additionally, hospitals typically have oncology divisions that conduct regular monitoring of CEA levels during chemotherapy or radiation treatment to evaluate treatment effectiveness and make necessary dosage adjustments. The rise in cancer cases globally and the increase in hospitalizations for cancer care are predicted to boost the need for CEA tests in medical facilities.

Laboratories are projected to grow at the fastest CAGR of 5.5% over the forecast period. Laboratories are essential in the CEA market as they conduct diagnostic tests on patient samples sourced from a range of healthcare facilities such as hospitals and clinics. Specialized testing services are provided using advanced equipment such as immunoassay analyzers for accurate measurement of CEA levels. Laboratories also supply findings to healthcare professionals who utilize this data to make informed choices about patient care. Increasingly, hospitals and clinics are turning to outsourcing laboratory services, which is anticipated to drive the need for CEA tests in laboratories. Moreover, progress in technology has resulted in the creation of automated systems capable of efficiently handling large amounts of samples, thereby heightening the need for these tests in labs.

Regional Insights & Trends

North America carcinoembryonic antigen market held 43.9% market share in 2023. It is expected to grow rapidly in the coming years due to the rising occurrence of different types of cancers among older and middle-aged populations.

U.S. Carcinoembryonic Antigen Market Trends

The carcinoembryonic antigen market in the U.S. dominated the North American carcinoembryonic antigen market with a share of 89.4% in 2023. It is attributed to its strong healthcare infrastructure, easy access to advanced cancer detection and treatment tools, and high cancer rates.

Europe Carcinoembryonic Antigen Market Trends

Europe carcinoembryonic antigen market was identified as a lucrative region in 2023 due to factors such as underutilized opportunities, ongoing enhancement of healthcare facilities, and increased patient awareness, contributing to its rapid growth. Several factors such as advanced healthcare facilities, increasing disposable income, and heightened awareness about cancer screening and early detection are driving the demand for CEA testing in this region.

The UK carcinoembryonic antigen market is expected to grow rapidly in the coming years due to the rising incidences of cancer. According to Macmillan Cancer Support, an organization working for cancer patients, there were more than 3 million people in UK that were living with cancer, rising to 4 million by 2030 and it will be 5.3 million by 2040.

The Germany carcinoembryonic antigen market held a substantial market share in 2023. This is due to the increasing prevalence of cancer in the country and country’s well-established healthcare infrastructure which supports the growth of CEA testing. As the cancer incidences are rising there is increasing demand for CEA in the healthcare settings including hospitals & laboratories.

Asia Pacific Carcinoembryonic Antigen Market Trends

Asia Pacific market is anticipated to witness significant growth in the coming years owing to the increasing number of cancer cases, a growing elderly population, advanced healthcare settings and growing awareness about cancer diagnosis and treatments.

The significant market share of carcinoembryonic antigen in China in 2023 can be attributed to the rapidly growing cancer cases in the country. According to ScienceDirect, a journal of the National Cancer Centre in China, there were 4,824,700 new cancer cases in 2022 and lung, colon-rectum, thyroid, liver and stomach cancer were the top five cancer types which accounted for 57.42% of new cancer cases.

The India carcinoembryonic antigen market held a substantial share due to several factors including India’s expanding healthcare infrastructure and awareness about cancer screening tests. According to National Centre for Disease Informatics and Research, approximately one in nine people in India is expected to face a cancer diagnosis during their lifetime.

Key Carcinoembryonic Antigen Company Insights

Some of the key companies in the carcinoembryonic antigen market include Quest Diagnostics Incorporated; F. Hoffmann-La Roche Ltd, Creative Diagnostics, Aviva Systems Biology Corporation, Abbott, Merck KGaA and Omega Diagnostics Ltd.

• F. Hoffmann-La Roche’s Diagnostics division offers solutions for in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management.

Carcinoembryonic Antigen Market Report Scope

Global Carcinoembryonic Antigen Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the carcinoembryonic antigen market report based on type, gender, product, test, end use, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Colorectal Cancer

  • Pancreatic Cancer

  • Ovarian Cancer

  • Breast Cancer

  • Thyroid Cancer

  • Others

• Gender Outlook (Revenue, USD Million, 2018 - 2030)

  • Male

  • Female

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • CD66a

  • CD66b

  • CD66c

  • CD66d

  • CD66e

  • CD66f

• Test Outlook (Revenue, USD Million, 2018 - 2030)

  • Molecular Test

  • Serology Test

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Mexico

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Thailand

    • Australia

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait